SRTA Strata Critical Medical, Inc.
Stock · NasdaqCM · United States · Healthcare · US0926671043
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Strata Critical Medical, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
5.56 USD
+5.70%
52-week range
3.95 – 6.50
Dividend yield—
Market cap496.6M
NowoTrade score
53 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:10. Information, not advice.
Results
Next results
02 Mar 2027
in 115 days · 08:00 · estimate -0.03
Last results
-0.09 vs -0.01 estimated
03 Nov 2026 · Miss -1,100.0%
Beat the estimate
7 of 12
5 missed · 0 in line
Average surprise
-184.9%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 02 Mar 2027 08:00 | -0.03 | — | — | Upcoming |
| 03 Nov 2026 08:00 | -0.01 | -0.09 | -1,100.0% | Miss |
| 04 Aug 2026 07:00 | -0.02 | -0.12 | -500.0% | Miss |
| 06 May 2026 07:00 | -0.04 | 0.04 | +212.0% | Beat |
| 03 Mar 2026 11:00 | -0.01 | -0.06 | -500.0% | Miss |
| 10 Nov 2025 07:00 | -0.02 | -0.12 | -500.0% | Miss |
| 05 Aug 2025 07:00 | -0.05 | -0.04 | +27.4% | Beat |
| 12 May 2025 07:00 | -0.10 | -0.07 | +28.0% | Beat |
| 13 Mar 2025 14:00 | -0.10 | -0.05 | +45.7% | Beat |
| 12 Nov 2024 07:00 | -0.02 | -0.01 | +66.1% | Beat |
| 07 Aug 2024 16:00 | -0.06 | -0.06 | +3.0% | Beat |
| 07 May 2024 13:00 | -0.11 | -0.10 | +8.8% | Beat |
| 12 Mar 2024 17:00 | -0.09 | -0.10 | -10.2% | Miss |
| 08 Nov 2023 07:00 | -0.06 | -0.02 | +67.6% | Beat |
| 09 Aug 2023 07:00 | -0.10 | -0.09 | +8.3% | Beat |
| 11 May 2023 08:00 | -0.16 | -0.14 | +11.5% | Beat |
| 16 Mar 2023 06:00 | -0.16 | -0.17 | -5.1% | Miss |
| 10 Nov 2022 16:00 | -0.13 | -0.09 | +30.3% | Beat |
| 09 Aug 2022 08:00 | -0.19 | -0.11 | +42.4% | Beat |
| 10 May 2022 07:00 | -0.20 | -0.15 | +22.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 197.1M | +34.3% | 41.3M | 21.0% | 0.48 | +236.3% | -59.9M |
| 2024 | 146.8M | -34.8% | -27.3M | -18.6% | -0.35 | +53.9% | -35.5M |
| 2023 | 225.2M | +54.1% | -56.1M | -24.9% | -0.76 | -100.0% | -34.5M |
| 2022 | 146.1M | — | -27.3M | -18.7% | -0.38 | — | -37.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 02 Dec 2024 – 06 Dec 2024 | 4.80 | 4.89 | 4.13 | 4.72 | -0.42% | 8,934,100 | |
| 25 Nov 2024 – 29 Nov 2024 | 3.38 | 5.17 | 3.30 | 4.74 | +43.64% | 11,265,800 | |
| 18 Nov 2024 – 22 Nov 2024 | 3.17 | 3.41 | 3.06 | 3.30 | +4.43% | 3,343,000 | |
| 11 Nov 2024 – 15 Nov 2024 | 3.92 | 3.98 | 3.11 | 3.16 | -15.28% | 5,914,500 | |
| 04 Nov 2024 – 08 Nov 2024 | 3.55 | 3.98 | 3.48 | 3.73 | +3.61% | 2,452,500 | |
| 28 Oct 2024 – 01 Nov 2024 | 3.57 | 3.91 | 3.52 | 3.60 | +1.69% | 2,115,600 | |
| 21 Oct 2024 – 25 Oct 2024 | 3.78 | 3.85 | 3.52 | 3.54 | -5.85% | 2,038,200 | |
| 14 Oct 2024 – 18 Oct 2024 | 3.52 | 3.77 | 3.41 | 3.76 | +6.82% | 1,793,600 | |
| 07 Oct 2024 – 11 Oct 2024 | 3.45 | 3.60 | 3.37 | 3.52 | +2.62% | 2,582,500 | |
| 30 Sep 2024 – 04 Oct 2024 | 2.92 | 3.48 | 2.86 | 3.43 | +16.27% | 2,495,000 | |
| 23 Sep 2024 – 27 Sep 2024 | 3.30 | 3.30 | 2.81 | 2.95 | -11.41% | 3,207,300 | |
| 16 Sep 2024 – 20 Sep 2024 | 3.16 | 3.36 | 3.13 | 3.33 | +4.72% | 2,261,100 | |
| 09 Sep 2024 – 13 Sep 2024 | 2.89 | 3.20 | 2.89 | 3.18 | +11.58% | 1,997,100 | |
| 03 Sep 2024 – 06 Sep 2024 | 3.14 | 3.16 | 2.81 | 2.85 | -8.95% | 1,517,300 | |
| 26 Aug 2024 – 30 Aug 2024 | 3.15 | 3.21 | 3.04 | 3.13 | +0.32% | 1,768,600 | |
| 19 Aug 2024 – 23 Aug 2024 | 3.03 | 3.17 | 2.93 | 3.12 | +2.63% | 2,066,600 | |
| 12 Aug 2024 – 16 Aug 2024 | 3.00 | 3.07 | 2.80 | 3.04 | +1.00% | 2,520,900 | |
| 05 Aug 2024 – 09 Aug 2024 | 2.70 | 3.33 | 2.60 | 3.01 | +4.51% | 4,341,500 | |
| 29 Jul 2024 – 02 Aug 2024 | 3.59 | 3.61 | 2.87 | 2.88 | -19.33% | 2,711,900 | |
| 22 Jul 2024 – 26 Jul 2024 | 3.65 | 3.79 | 3.47 | 3.57 | -1.92% | 1,990,400 | |
| 15 Jul 2024 – 19 Jul 2024 | 3.48 | 3.79 | 3.33 | 3.64 | +5.51% | 5,569,700 | |
| 08 Jul 2024 – 12 Jul 2024 | 3.45 | 3.56 | 3.35 | 3.45 | +0.29% | 4,880,900 | |
| 01 Jul 2024 – 05 Jul 2024 | 3.48 | 3.52 | 3.30 | 3.44 | -1.15% | 1,608,200 | |
| 24 Jun 2024 – 28 Jun 2024 | 3.16 | 3.52 | 3.07 | 3.48 | +10.13% | 1,909,100 | |
| 17 Jun 2024 – 21 Jun 2024 | 2.95 | 3.50 | 2.95 | 3.16 | +7.85% | 2,301,000 |
Page 5 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Strata Critical Medical Inc (SRTA) (Q3 2026) Earnings Call Highlights: Revenue Surges 50% as ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 23:04
- Strata Critical Medical to Present at the UBS Global Healthcare Conference (opens in a new tab) 03 Nov 2026 21:05
- Strata Critical Medical (SRTA) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 20:40
- Strata Critical Medical Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 03 Nov 2026 15:14
- Strata Critical Medical Announces Third Quarter 2026 Results (opens in a new tab) 03 Nov 2026 12:00
- Strata Critical Medical, Inc. (SRTA) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 11:55
- Strata Critical Medical Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 03 Nov 2026 09:58
- Strata Critical Medical Affirms FY2026 Sales Guidance of $285.000M-$295.000M vs $290.804M Est (opens in a new tab) Benzinga · 03 Nov 2026 08:02
- Strata Critical Medical Q3 EPS $(0.09) Misses $(0.01) Estimate, Sales $74.081M Beat $72.669M Estimate (opens in a new tab) Benzinga · 03 Nov 2026 08:00
- Strata Critical Medical and 3 More Stocks See Action From Activist Investors (opens in a new tab) Barrons.com · 23 Oct 2026 23:47
- Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock? (opens in a new tab) Zacks · 24 Aug 2026 17:00
- Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect? (opens in a new tab) Zacks · 24 Aug 2026 14:55
- Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 11 Aug 2026 18:35
- Immersion Investment Views Strata Critical Medical (SRTA) as a “Babushka Doll” (opens in a new tab) Insider Monkey · 11 Aug 2026 14:44
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 5.26 USD
- Market cap
- 496.6M
- Exchange
- NasdaqCM
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 17.5 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 15.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.1 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Price / book | 1.8× | Fair | 3.94× |
| Price / sales | 1.77× | Good | 3.37× |
| EV / EBITDA | 52.24× | Weak | 12.96× |
| Free cash flow yield | 0.4% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 21.6% | Fair | 59.2% |
| Operating margin | -4.3% | Weak | 7.4% |
| Net margin | -8.8% | Weak | 3.4% |
| Return on equity | -7.6% | Weak | 5.7% |
| Return on assets | -2.5% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 10.5% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.46× |
| Net debt / EBITDA | -4.33× | Good | 1.5× |
| Current ratio | 2.77× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow SRTA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.